SRRK earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -14.00. Updated 2026-07-23.
Scholar Rock Holding (SRRK) Research Hub
Scholar Rock Holding (SRRK) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 55.41 USD (+1.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.00, market cap 5.67B. This hub links to the full technical, earnings and options research available for SRRK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 55.41 USD (+1.45%) |
| 52-week range | 44.31 USD – 61.76 USD |
| Trend regime | Range |
| 14-day RSI | 55.8 (Bullish) |
| Trailing P/E | -14.00 |
| Market cap | 5.67B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for SRRK
Covered Call on SRRK: how it works, illustrative setup around the real 55.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SRRK: how it works, illustrative setup around the real 55.41 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SRRK: how it works, illustrative setup around the real 55.41 USD price, max profit/loss, breakeven and when to use it. Educational.
SRRK technical analysis: range, last 55.41 USD, RSI 55.8, 52w range 44.31 USD–61.76 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SRRK in?
Scholar Rock Holding (SRRK) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SRRK in an uptrend or downtrend?
As of 2026-09-11, SRRK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SRRK's trailing P/E ratio?
SRRK's trailing P/E is -14.00, with a market cap of 5.67B. See the earnings research page for full valuation detail.
When does SRRK next report earnings?
SRRK is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.84 USD.